作者
Zicheng Wang,Yingying Yu,Wanjun Shao,Yuhao Zhao,Zhe Li,Jiaming Han,Jingyu Wen,Yongchun Meng,Ying Lin,Shaoping Wang
摘要
Puerarin is a natural flavonoid glycoside extracted from the traditional Chinese medicine Puerariae Lobatae Radix or Pueraria lobata (Willd), known for its hepatoprotective properties. While prior studies indicate that PR can mitigate ALD, the underlying mechanisms by which PR exerts its anti-ALD effects via intestinal flora remain poorly understood. This study aimed to investigate the metabolic differences of PR in normal and ALD model rats were analyzed using UHPLC-HRMS. Further validation of PR metabolic products in vivo through in vitro fecal fermentation. Additionally, the relationship between the anti-ALD properties of PR and intestinal flora was explored using 16S rRNA sequencing technology, with confirmation obtained from fecal microbiota transplantation (FMT) experiments and functional strain experiments. Finally, through non-targeted metabolomics and liver transcriptomics combined with in vitro cell pharmacological studies, the mechanism of action of PR and its in vitro fermentation metabolites against ALD was explored. In the PR metabolic test, 20 metabolites were identified in the serum, urine, and feces of normal and ALD model rats, primarily associated with reactions including deglycosylation, hydrogenation, aldehyde esterification, hydroxylation, and methylation. 6 metabolites were verified in vitro transformation system. Subsequently, we used FMT experiments and 16S rRNA sequencing to find that intestinal flora imbalance can lead to liver disease and PR can improve liver disease by regulating intestinal flora. Based on multi-omics analysis and in vitro pharmacological activity analysis, PR and its in vitro fermented metabolites inhibit MAPK and Nrf2 pathways, further reducing inflammation and oxidative stress. The results of this study show that PR can improve ALD, with its mechanism of action potentially involving regulation of the intestinal flora, suppression of inflammatory responses, and inhibition of oxidative stress. • First, A comprehensive metabolic analysis strategy was established to compare the metabolic mechanisms of puerarin in both normal and ALD model states. • Second, In order to verify the mediating role of intestinal flora between puerarin and alcoholic liver disease, an in vitro fermentation system was established at different time points, and the in vivo metabolic results were further verified. • Three, In order to verify that puerarin can improve alcoholic liver disease by regulating intestinal flora, we further confirmed that intestinal flora imbalance can lead to liver disease through flora transplantation experiments and also confirmed that puerarin can improve liver disease by regulating intestinal flora. • Finally, the pharmacological mechanism of metabolites after puerarin fermentation was further explored by HepG2 cells for the first time.